| __timestamp | BioMarin Pharmaceutical Inc. | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 8185000 |
| Thursday, January 1, 2015 | 402271000 | 8871000 |
| Friday, January 1, 2016 | 476593000 | 9645000 |
| Sunday, January 1, 2017 | 554336000 | 12387000 |
| Monday, January 1, 2018 | 604353000 | 14381000 |
| Tuesday, January 1, 2019 | 680924000 | 19238000 |
| Wednesday, January 1, 2020 | 737669000 | 17425000 |
| Friday, January 1, 2021 | 759375000 | 23040000 |
| Saturday, January 1, 2022 | 854009000 | 25116000 |
| Sunday, January 1, 2023 | 937300000 | 51953000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. BioMarin Pharmaceutical Inc. and CymaBay Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, BioMarin's SG&A expenses surged by over 200%, reflecting its expansive growth strategy. In contrast, CymaBay's expenses increased by approximately 535%, albeit from a much smaller base, indicating a more aggressive scaling approach.
BioMarin's consistent increase in SG&A costs, peaking at nearly $937 million in 2023, suggests a robust investment in administrative capabilities and market expansion. Meanwhile, CymaBay's expenses, though significantly lower, reached $52 million in the same year, highlighting its strategic focus on lean operations. This comparison underscores the diverse strategies employed by biotech firms in optimizing operational costs while pursuing growth.
SG&A Efficiency Analysis: Comparing Vertex Pharmaceuticals Incorporated and CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: GSK plc vs CymaBay Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Soleno Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs Geron Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: CymaBay Therapeutics, Inc. vs MiMedx Group, Inc.